Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.

Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 40

Pages Range: 3741-3749

Journal Issue: 32

DOI: 10.1200/JCO.22.00202

Abstract

PURPOSE: The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. PATIENTS AND METHODS: The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. RESULTS: For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. CONCLUSION: The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.

Authors with CRIS profile

Involved external institutions

Eberhard Karls Universität Tübingen Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Universitätsklinikum Würzburg Germany (DE) Johannes Wesling Klinikum Minden Germany (DE) Universitätsklinikum Halle (Saale) Germany (DE) Universitätsklinikum Magdeburg A.ö.R. Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum Germany (DE) Universitätsklinikum Essen Germany (DE) Städtisches Klinikum Dessau Germany (DE) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Princess Máxima Center Netherlands (NL) Aix-Marseille University / Aix-Marseille Université France (FR) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Military Medical Academy (Serbia) / Војномедицинска академија / Vojnomedicinska akademija (VMA) Serbia (RS) University of Sydney (USYD) Australia (AU) UPMC Hillman Cancer Center United States (USA) (US) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV) Switzerland (CH) Catholic University of the Sacred Heart / Università Cattolica del Sacro Cuore Italy (IT) University of Manchester United Kingdom (GB)

How to cite

APA:

Garbe, C., Keim, U., Amaral, T., Berking, C., Eigentler, T.K., Flatz, L.,... Lorigan, P.C. (2022). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 40(32), 3741-3749. https://doi.org/10.1200/JCO.22.00202

MLA:

Garbe, Claus, et al. "Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment." Journal of Clinical Oncology 40.32 (2022): 3741-3749.

BibTeX: Download